REPORTS

Let’s Pullulate and Expand Your Business

Preventable Vaccines Market - Global Professional Analysis and Forecast to 2026

Feb 02, 2020  |  175 PAGES  |  REPORT CODE: CMM264657
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Preventable Vaccines market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.6% during the forecast period.

This report presents the market size and development trends by detailing the Preventable Vaccines market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Preventable Vaccines market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Preventable Vaccines industry and will help you to build a panoramic view of the industrial development.

Preventable Vaccines Market, By Type:

  • Adult Preventable Vaccines

  • Pediatric Preventable Vaccines

Preventable Vaccines Market, By Application:

  • Bacterial Diseases

  • Virus Diseases

Some of the leading players are as follows:

  • Crucell

  • LG Life Sciences

  • GlaxoSmithKline

  • Merck

  • Panacea Biotec

  • Shenzhen Kangtai Biological Products

  • Baxter

  • Protein Sciences

  • Sinovac Biotech

  • Pfizer

  • Roche

  • Dynavax

  • Sanofi

  • Serum Institute of India

  • AstraZeneca

  • Bharat Biotech

  • Lupin

  • Abbott

  • Mitsubishi Tanabe Pharma

  • Novartis

  • Takeda Pharmaceutical

  • Valeant Pharmaceuticals

  • Janssen Pharmaceuticals

  • S K Chemicals

  • Bavarian Nordic

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Preventable Vaccines Market: Technology Type Analysis

  • 4.1 Preventable Vaccines Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Preventable Vaccines Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Adult Preventable Vaccines

    • 4.3.2 Pediatric Preventable Vaccines

5 Preventable Vaccines Market: Product Analysis

  • 5.1 Preventable Vaccines Product Market Share Analysis, 2018 & 2026

  • 5.2 Preventable Vaccines Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Preventable Vaccines Market: Application Analysis

  • 6.1 Preventable Vaccines Application Market Share Analysis, 2018 & 2026

  • 6.2 Preventable Vaccines Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Bacterial Diseases

    • 6.3.2 Virus Diseases

7 Preventable Vaccines Market: Regional Analysis

  • 7.1 Preventable Vaccines Regional Market Share Analysis, 2018 & 2026

  • 7.2 Preventable Vaccines Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Crucell

    • 9.1.1 Crucell Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 LG Life Sciences

    • 9.2.1 LG Life Sciences Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 GlaxoSmithKline

    • 9.3.1 GlaxoSmithKline Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Merck

    • 9.4.1 Merck Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Panacea Biotec

    • 9.5.1 Panacea Biotec Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Shenzhen Kangtai Biological Products

    • 9.6.1 Shenzhen Kangtai Biological Products Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Baxter

    • 9.7.1 Baxter Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Protein Sciences

    • 9.8.1 Protein Sciences Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Sinovac Biotech

    • 9.9.1 Sinovac Biotech Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Pfizer

    • 9.10.1 Pfizer Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Roche

    • 9.11.1 Roche Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Dynavax

    • 9.12.1 Dynavax Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Sanofi

    • 9.13.1 Sanofi Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Serum Institute of India

    • 9.14.1 Serum Institute of India Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 AstraZeneca

    • 9.15.1 AstraZeneca Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Bharat Biotech

    • 9.16.1 Bharat Biotech Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Lupin

    • 9.17.1 Lupin Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Abbott

    • 9.18.1 Abbott Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 Mitsubishi Tanabe Pharma

    • 9.19.1 Mitsubishi Tanabe Pharma Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 Novartis

    • 9.20.1 Novartis Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

  • 9.21 Takeda Pharmaceutical

    • 9.21.1 Takeda Pharmaceutical Company overview

    • 9.21.2 Financial performance

    • 9.21.3 Product benchmarking

    • 9.21.4 Strategic initiatives

    • 9.21.5 SWOT analysis

  • 9.22 Valeant Pharmaceuticals

    • 9.22.1 Valeant Pharmaceuticals Company overview

    • 9.22.2 Financial performance

    • 9.22.3 Product benchmarking

    • 9.22.4 Strategic initiatives

    • 9.22.5 SWOT analysis

  • 9.23 Janssen Pharmaceuticals

    • 9.23.1 Janssen Pharmaceuticals Company overview

    • 9.23.2 Financial performance

    • 9.23.3 Product benchmarking

    • 9.23.4 Strategic initiatives

    • 9.23.5 SWOT analysis

  • 9.24 S K Chemicals

    • 9.24.1 S K Chemicals Company overview

    • 9.24.2 Financial performance

    • 9.24.3 Product benchmarking

    • 9.24.4 Strategic initiatives

    • 9.24.5 SWOT analysis

  • 9.25 Bavarian Nordic

    • 9.25.1 Bavarian Nordic Company overview

    • 9.25.2 Financial performance

    • 9.25.3 Product benchmarking

    • 9.25.4 Strategic initiatives

    • 9.25.5 SWOT analysis

 

The List of Tables and Figures (Totals 67 Figures and 125 Tables)

  • Figure Adult Preventable Vaccines Preventable Vaccines market, 2015 - 2026 (USD Million)

  • Figure Pediatric Preventable Vaccines Preventable Vaccines market, 2015 - 2026 (USD Million)

  • Figure Bacterial Diseases market, 2015 - 2026 (USD Million)

  • Figure Virus Diseases market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Preventable Vaccines market, by country, 2015 - 2026 (USD Million)

  • Table North America Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table North America Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table North America Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Canada Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Canada Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Europe Preventable Vaccines market, by country, 2015 - 2026 (USD Million)

  • Table Europe Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Europe Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Europe Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Germany Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Germany Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table France Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table France Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Italy Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Italy Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Spain Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Spain Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Preventable Vaccines market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table China Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table China Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Japan Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Japan Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table India Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table India Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Preventable Vaccines market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table MEA Preventable Vaccines market, by country, 2015 - 2026 (USD Million)

  • Table MEA Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table MEA Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table MEA Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Preventable Vaccines market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Preventable Vaccines market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Preventable Vaccines market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Crucell Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table LG Life Sciences Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Panacea Biotec Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Shenzhen Kangtai Biological Products Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Baxter Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Protein Sciences Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sinovac Biotech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Roche Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Dynavax Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Serum Institute of India Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bharat Biotech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Lupin Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Abbott Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Mitsubishi Tanabe Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Takeda Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Valeant Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Janssen Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table S K Chemicals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bavarian Nordic Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top